A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Atrasentan (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms SONAR
- Sponsors AbbVie
- 05 Aug 2017 Planned number of patients changed from 6200 to 5500.
- 14 Apr 2017 Planned End Date changed from 1 Nov 2018 to 8 Apr 2020.
- 05 Nov 2015 Interim results (n=4148) of population enriched design were presented at the 22nd World Congress of Neurology.